18075-64-4

Basic information

• Product Name: 1-Phenyl-1H-imidazole-4-carboxylic acid
• Synonyms: 1-Phenyl-1H-imidazole-4-carboxylic acid
• CAS NO: 18075-64-4
• Molecular Formula: C₁₀H₈N₂O₂
• Molecular Weight: 188.185
• Mol File: 18075-64-4.mol

Chemical Properties

• Boiling Point: 424.516°C at 760 mmHg
• Flash Point: 210.54°C
• Appearance: /
• Density: 1.284g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.48±0.10(Predicted)
• CAS DataBase Reference: 1-Phenyl-1H-imidazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Phenyl-1H-imidazole-4-carboxylic acid(18075-64-4)
• EPA Substance Registry System: 1-Phenyl-1H-imidazole-4-carboxylic acid(18075-64-4)

Safety Data

• Hazardous Substances Data: 18075-64-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenyl-1H-imidazole-4-carboxylic acid is used as an active pharmaceutical ingredient for its potential anti-inflammatory and antimicrobial properties. Its ability to modulate biological processes makes it a candidate for the development of new drugs targeting inflammation and infections.
Used in Organic Synthesis:
PHICA is used as a key intermediate in the synthesis of other organic compounds. Its reactivity and structural features facilitate the creation of a variety of chemical entities, contributing to the advancement of organic chemistry and the discovery of new molecules with therapeutic potential.
Used in Anticancer Research:
1-Phenyl-1H-imidazole-4-carboxylic acid derivatives are used as anticancer agents in research settings. Studies are focused on understanding their mechanisms of action and evaluating their efficacy against various types of cancer, with the aim of developing novel therapeutics for cancer treatment.
Overall, 1-Phenyl-1H-imidazole-4-carboxylic acid is a versatile chemical with a broad spectrum of potential applications, particularly in the fields of medicine and pharmaceuticals, where its unique properties are being harnessed to address various health challenges.

InChI:InChI=1/C10H8N2O2/c13-10(14)9-6-12(7-11-9)8-4-2-1-3-5-8/h1-7H,(H,13,14)

Upstream product

• 116343-89-6 methyl 1-phenyl-1H-imidazole-4-carboxylate 
• 197079-08-6 ethyl 1-phenyl-1H-imidazole-4-carboxylate 
• 591-50-4 iodobenzene 
• 103-70-8 Formanilid 
• 1197040-29-1 phenyl isocyanate 
• 62-53-3 aniline 

Downstream Products

• 1188373-49-0 1-phenyl-1H-imidazole-4-carboxylic acid {2-oxo-2-[4-(3-trifluoromethylphenoxy)piperidin-1-yl]ethyl}amide 
• 1188373-50-3 1-phenyl-1H-imidazole-4-carboxylic acid {2-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-2-oxoethyl}amide 
• 1188373-85-4 1-phenyl-1H-imidazole-4-carboxylic acid {2-[4-(2,5-difluorophenoxy)piperidin-1-yl]-2-oxoethyl}amide 
• 1232028-07-7 1-phenyl-1H-imidazole-4-carboxylic acid {2-[4-(2-chloro-5-fluoro-benzoyl)-piperazin-1-yl]-2-oxo-ethyl}-amide 
• 1391625-85-6 (3S,6S)-3,6-diisobutyl-4-(1-phenyl-1H-imidazole-4-carbonyl)-piperazin-2-one 
• 1613022-33-5 C₂₁H₂₀N₆O*C₂HF₃O₂ 
• 1613022-32-4 1-phenyl-1H-imidazole-4-carboxylic acid (1-pyrrolo[1,2-a]pyrazin-1-yl-pyrrolidin-3-yl)amide 
• 1613022-35-7 1-phenyl-1H-imidazole-4-carboxylic acid[1-(3-methyl-pyrrolo[1,2-a]pyrazin-1-yl)-pyrrolidin-3-yl]-amide 
• 1613021-87-6 (S)-N-(1-([1,2,4]triazolo[4,3-a]pyrazin-8-yl)pyrrolidin-3-yl)-1-phenyl-1H-imidazole-4-carboxamide 

Relevant articles and documents

4-phenoxyl substituted quinoline compound containing 2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one and imidazole and application of compound

The invention relates to a quinoline derivative shown as the general formula I and containing 2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one and imidazole, and pharmaceutically acceptable salt, hydrate, solvate or prodrug of the quinoline derivative. In the general formula I, Ar, R1, R2, L, and n have meanings as the description defined. The invention further relates to a great c-Met kinase inhibiting effect of the compound shown as the general formula I, and applications of pharmaceutically acceptable salt, hydrate, solvate or prodrug of the compound to prepare medicines for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, particularly an application of preparing a medicine for treating and/or preventing cancer.

Novel Compounds

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.

Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies

The synthesis and structure-activity relationship studies of imidazoles are described. The target compounds 6-20 represent a novel chemotype of potent and CB2/CB1 selective cannabinoid CB2 receptor antagonists/inverse agonists with very high binding efficiencies in combination with favourable log P and calculated polar surface area values. Compound 12 exhibited the highest CB2 receptor affinity (Ki = 1.03 nM) in this series, as well as the highest CB2/CB1 subtype selectivity (>9708-fold).

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE

The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE

The present invention relates to piperidine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

Imidazole derivatives

Novel imidazole derivatives are disclosed. These compounds have a good affinity to the NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation. These compounds are useful in the control or treatment of diseases mediated by this receptor.